Story
Viking Therapeutics Named Top Biotech Pick by Cantor Fitzgerald on Obesity Drug Hopes

Cantor Fitzgerald has initiated coverage on Viking Therapeutics (NASDAQ: VKTX), designating the company as a top pick in the biotechnology sector. The investment firm assigned an Overweight rating and set a price target of $111 per share, signaling significant upside from its current trading levels.
Analyst's Thesis
The bullish outlook from Cantor is primarily driven by the potential of Viking's lead drug candidate, VK2735, an injectable treatment for obesity. The analyst note highlighted the drug's promising clinical data, which suggests a competitive profile in the rapidly expanding market for weight-loss therapies.
According to Cantor, VK2735's efficacy and safety profile could position it as a strong contender against established treatments. The firm believes the market is currently underappreciating the commercial potential of Viking's pipeline, presenting a favorable risk/reward opportunity for investors.
Competitive Landscape
Viking Therapeutics is entering a market dominated by pharmaceutical giants Novo Nordisk and Eli Lilly, whose GLP-1 agonist drugs Wegovy and Zepbound have seen massive commercial success. These treatments have set a high bar for both efficacy and safety in the obesity space.
AdFor Viking to capture market share, VK2735 will need to demonstrate clear advantages, such as superior weight loss, a better side-effect profile, or more convenient dosing. Investors will be closely watching upcoming clinical trial results to assess its potential to differentiate itself from the competition.
What It Means for Investors
The initiation of coverage provides a new, positive data point for investors evaluating Viking's stock. The $111 price target suggests that Cantor's model anticipates successful clinical development and a significant share of the multi-billion dollar obesity market.
However, as with any clinical-stage biotechnology company, investing in Viking carries inherent risks. The stock's performance will be heavily dependent on future trial outcomes and subsequent regulatory decisions from agencies like the U.S. Food and Drug Administration (FDA).
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.